We were privileged to attend the 7th Annual Digital Biomarkers in Clinical Trials Summit at the Roche Headquarters in Basel on June 26th, 2024. Over 300 attendees attended the consortium, including pharma, biotech, and digital health executives, to discuss innovative strategies to improve trials through the use of digital biomarkers.

In prior years, the summit focused primarily on initiatives that global experts were planning to explore. This year was notably exciting as we began to see evidence and knowledge that resulted from these initiatives. Panelists discussed successes, challenges, and the current state of digital biomarkers across neuroscience, oncology, immunology and cardiovascular therapeutic areas, as well as multi-stakeholder perspectives on digital endpoint development and adoption. 

Specifically, panelists highlighted notable advances over the past few years that have enabled better positioning of digital endpoints to more accurately assess disease impacts. Panelists also highlighted published evidence on how digital measures may significantly reduce sample size and enable targeted cohort-specific recruitment across indications.

At the summit, our CEO, Chris Benko, presented our work on a patient centric prognostic biomarker for Sickle Cell Disease. The ability to predict, identify and classify vaso-occlusive crises may enable earlier intervention, increase event yield to power revised endpoints, reduce sample size, and improve recruitment. Additionally, Koneksa had a booth where we demonstrated our Koneksa Platform and supported devices. The day concluded with a Koneksa sponsored evening reception at the Krafft Hotel overlooking the Rhine River. 

As the digital biomarker landscape evolves, Koneksa remains at the forefront, constantly developing, testing, and validating digital biomarkers to enable our clients to assess the impact of their treatments.